The Government of India is preparing to review drug approvals issued over the past 81 years in an effort to strengthen medicine safety, improve regulatory oversight and update official records. The exercise will verify approvals granted since 1945, identify gaps in existing documentation and trace medicines whose approval details are missing from the central database.
CDSCO Records to Be Updated
According to government sources, the initiative will focus on updating records maintained by the Central Drugs Standard Control Organisation. Authorities will reconcile drug licences and approvals issued since India’s drug regulatory framework was first established in 1945.
Officials plan to create a comprehensive digital repository of drug approvals that may not have been captured in the existing central database. The exercise is expected to organise decades of regulatory records and improve oversight of medicines available in the market.
Legacy Approvals Under Scrutiny
Government officials are concerned that some drug formulations approved many years ago may still be in circulation despite not meeting present standards of safety, quality and efficacy. A fresh review of legacy approvals and licences has therefore been considered necessary.
As part of the process, authorities will examine whether approvals granted at different points in time match available regulatory documentation. If any approved drug is found missing from the central database, supporting records will be verified and updated.
Digital Repository Planned
Experts believe that a unified digital repository covering more than eight decades of drug approvals will improve transparency in India’s pharmaceutical regulatory system. It will also help regulators identify medicines backed by valid approvals and determine where further scrutiny may be required.
The initiative is expected to benefit the pharmaceutical industry, regulators and the public healthcare system. An updated database could streamline future processes related to drug approvals, regulatory monitoring and compliance.
The government believes the large-scale audit will make the drug approval system more transparent, improve the reliability of regulatory records and strengthen efforts to ensure the safety, quality and effectiveness of medicines available in the country.
